Accepted at: Sep, 20, 2024
2:46 a.m.
Author:
phoebeee
Related Deck:
1675118865074
Accepted
Rationale for new note
new card
Text
What antihypertensive classes are contraindicated in patients with bilateral renal artery stenosis?
{{c1::Angiotensin converting enzyme inhibitors (ACEIs)
and
Angiotensin II receptor blockers (ARBs)}}
{{c1::Angiotensin converting enzyme inhibitors (ACEIs)
and
Angiotensin II receptor blockers (ARBs)}}
Text
What <b>antihypertensive classes</b> are <i>contraindicated </i>in patients with <b>bilateral renal artery stenosis</b>?<br><br>{{c1::<b>Angiotensin converting enzyme inhibitors</b> (ACEIs)<br> and <br><b>Angiotensin II receptor blockers</b> (ARBs)}}
Extra
ACE inhibitors and ARBs cause vasodilation of the efferent arteriole in the glomerulus creating a risk of azotemia in patients with severe unilateral or bilateral renal artery stenosis
Extra
<b>ACE inhibitors</b> and <b>ARBs </b>cause vasodilation of the efferent arteriole in the glomerulus creating a risk of <b>azotemia </b>in patients with severe unilateral or <b>bilateral</b> <b>renal artery stenosis</b>
Extra (Synced)
Empty field
Extra (Synced)
Personal Notes
Empty field
Personal Notes
Missed Questions
Empty field
Missed Questions
eTG Complete
Empty field
eTG Complete
Talley & O'Connor
Empty field
Talley & O'Connor
Additional Resources
Empty field
Additional Resources
Additional Resources (Synced)
Empty field
Additional Resources (Synced)
Source
eTG - Hypertension and blood pressure reduction https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1&guidelinename=auto§ionId=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1#c_CVG_Hypertension-and-blood-pressure-reductiontopic_1 Published June 2023, Accessed 19 September 2024
Source
eTG - Hypertension and blood pressure reduction <a href="https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1&guidelinename=auto§ionId=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1#c_CVG_Hypertension-and-blood-pressure-reductiontopic_1">https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1&guidelinename=auto&sectionId=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1#c_CVG_Hypertension-and-blood-pressure-reductiontopic_1</a> Published June 2023, Accessed 19 September 2024<br>
One by one
Empty field
One by one
Tags
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Captopril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Enalapril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Fozinopril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Fosinopril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Lisinopril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Perindopril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Quinapril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Ramipril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Trandolapril::04_Contraindications/Precautions
#Malleus_CM::#Resources_by_Rotation::Internal_Medicine::Cardiology
#Malleus_CM::#Resources_by_Rotation::General_Practice
#Malleus_CM::#Resources_by_Rotation::Internal_Medicine
#Malleus_CM::#eTG_Complete::Cardiovascular::Blood_pressure_reduction::Hypertension_and_blood_pressure_reduction
#Malleus_CM::#Subjects::Cardiology::09_Hypertension::Essential_Hypertension::12_Screening/Prevention
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Candesartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Eprosartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Irbesartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Losartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Olmesartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Telmisartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Valsartan::04_Contraindications/Precautions
#Malleus_CM::#Subjects::Cardiology::09_Hypertension::Renal_Artery_Stenosis::11_Complications/Prognosis